CRISPR crops could reach $3B by 2030. See how gene editing fights climate change, boosts yields 15-20%, and improves food security.
Aaron Frost
·
85% of new businesses fail to scale. Learn why targeting specific customer segments boosts retention by 30% and revenue by 2.5x.
·
Iambic's $2.5B IPO signals a new biotech era. Learn what drives premium valuations now, distinguishing true innovation from speculation.
·
Founders: Understand 2025 cap table dilution risks from complex notes. Model scenarios to protect equity, control. 0.5% difference is $100k+.
·
Goldstar's new product owner role signals a key 2026 digital shift. Learn why this move prioritizes customers and accountability over old methods.
·
·
6 min read
Cyberattacks on global trade rose 15% in 2025. Learn how MFA and ZTNA can cut risk by 90% and protect your supply chain.
·
·
9 min read
Pharma startups face 2026 compliance demands. Learn why proactive regulatory strategy, allocating 15% R&D budget, and eCTD 4.0 are critical.
·
·
7 min read
Is AbbVie's aggressive biotech partnership model sustainable? Learn how its focus on late-stage assets, like Cerevel Therapeutics, shapes its future.
·
·
6 min read
2026 drug pricing debates threaten biotech startups. Learn how small firms can advocate for innovation and survive amidst calls for lower costs.
·
·
8 min read
Big Pharma spent $300M+ lobbying in 2025. See how this distorts policy, hurting biotech startups and innovation. What to watch next.
·
·
7 min read
